We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Radioembolization with Yttrium-90 Microspheres (SIRT) in Pancreatic Cancer Patients with Liver Metastases: Efficacy, Safety and Prognostic Factors.
- Authors
Michl, M.; Haug, A.R.; Jakobs, T.F.; Paprottka, P.; Hoffmann, R.-T.; Bartenstein, P.; Boeck, S.; Haas, M.; Laubender, R.P.; Heinemann, V.
- Abstract
Objective: To analyze the clinical efficacy of 90Y radioembolization in liver metastases from pancreatic cancer, to describe treatment toxicities and to identify biomarkers as predictors of outcome. Methods: Data from 19 pancreatic cancer patients (9 females/10 males) who had received 90Y radioembolization for metastatic liver disease between 06/2004 and 01/2011 were analyzed retrospectively. Results: The median age at 90Y radioembolization was 63 years (range 43-77). In 16 patients, previous palliative gemcitabine-based chemotherapy was given for metastatic disease. Objective response in the liver after 90Y radioembolization was 47%. Median local progression-free survival in the liver was 3.4 months (range 0.9-45.0). Median overall survival (OS) was 9.0 months (range 0.9-53.0) and 1-year survival was 24%. Cox regression models for baseline biomarkers at 90Y radioembolization revealed correlations of increased carbohydrate antigen 19-9 (p = 0.02) and C-reactive protein (p = 0.03) with shorter OS. Short-term adverse events (nausea, vomiting, fatigue, fever and abdominal pain) did not exceed grade 3. As long-term adverse events, liver abscesses, gastroduodenal ulceration, cholestasis and cholangitis, ascites and spleen infarction were observed. Conclusion:90Y radioembolization is able to induce an encouraging local response rate of liver metastases of pancreatic cancer patients. Most short-term toxicities are manageable; however, patients should be followed up carefully for severe long-term toxicities. © 2013 S. Karger AG, Basel
- Subjects
GERMANY; CANCER treatment; METASTASIS; ACADEMIC medical centers; PANCREATIC tumors; CONFIDENCE intervals; HEALTH outcome assessment; SAFETY; SURVIVAL; TREATMENT effectiveness; THERAPEUTIC embolization; PROPORTIONAL hazards models; PATIENT selection; DATA analysis software; DESCRIPTIVE statistics; KAPLAN-Meier estimator; PROGNOSIS; TUMOR treatment
- Publication
Oncology, 2014, Vol 86, Issue 1, p24
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000355821